Elevance Health Exceeds Q1 2026 Earnings Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Source: seekingalpha
Elevance Health's stock price increased by 3.02% as it reached a 20-day high, reflecting positive investor sentiment following strong earnings results.
The company reported an adjusted diluted EPS of $12.58 for Q1 2026, exceeding expectations by $1.77, driven by strong underlying business performance and prompting an increase in full-year EPS guidance to at least $26.75. Additionally, operating revenue reached $49.5 billion, indicating sustained competitiveness in the market. Despite ongoing legal investigations related to CMS sanctions, the strong earnings report has bolstered investor confidence.
This positive financial performance, combined with strategic initiatives such as AI investment and share repurchases, positions Elevance Health for continued growth, even amidst external challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELV
Wall Street analysts forecast ELV stock price to fall
15 Analyst Rating
11 Buy
4 Hold
0 Sell
Moderate Buy
Current: 408.170
Low
332.00
Averages
389.07
High
425.00
Current: 408.170
Low
332.00
Averages
389.07
High
425.00
About ELV
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
2027 Health Insurance Premiums May Rise 14%
- Premium Increase Trend: KFF's analysis reveals that 77 insurers across 16 states and Washington, D.C. are proposing a median premium increase of 14% for 2027, following a 20% rise in 2026, marking two consecutive years of double-digit hikes that exacerbate affordability issues.
- Enrollment Decline: Approximately 19 million people are covered under the Affordable Care Act, but enrollment has dropped by about 4 million this year due to the expiration of enhanced COVID-era subsidies, indicating that high premiums are deterring potential enrollees.
- Loss of Healthy Consumers: KFF highlights that rising premiums and the loss of subsidies discourage healthier individuals from enrolling, leaving insurers with a sicker member pool and higher medical costs, with insurers attributing roughly 4 percentage points of their requested premium increases for 2027 to this trend.
- Rising Medical Costs: Insurers cite increasing medical expenses, inflation, higher labor costs, and growing expenditures on GLP-1 weight-loss and diabetes treatments as key factors driving their need to raise premiums, reflecting the multifaceted pressures facing the industry.
See More
Cash-Generating Stocks with Growth Potential
- RingCentral's Declining Performance: Despite a free cash flow margin of 21.2%, RingCentral's average billings growth of only 5.2% over the past year indicates waning customer confidence, with projected sales growth slowing to 4.5% over the next 12 months, potentially diminishing its competitive edge.
- Avery Dennison's Growth Struggles: With a free cash flow margin of 9.3%, Avery Dennison has fallen short of organic revenue growth benchmarks, and its projected sales growth of just 3.8% for the next year, coupled with a mere 4.3% annual EPS growth over five years, suggests a need for product and strategy improvements.
- Elevance Health's Strong Potential: Elevance Health, with a free cash flow margin of 3.3%, boasts a 9.9% annualized sales growth and a substantial revenue base of $198.3 billion, providing leverage in the health insurance market, indicating a promising investment opportunity.
- Market Outlook Analysis: While RingCentral and Avery Dennison face growth challenges, Elevance Health's robust performance and market position make it a stock to watch, prompting investors to carefully assess the future market performance of these companies.
See More
Elevance Health Sues CMS Over Medicare Advantage Ratings
- Lawsuit Background: Elevance Health has filed a lawsuit against the Centers for Medicare & Medicaid Services (CMS), alleging unfair adjustments to a competitor's Medicare Advantage Star Ratings after finalization, claiming this created an uneven competitive landscape.
- Financial Impact: Elevance estimates that the disputed CMS decision cost it approximately $115 million in Medicare Advantage quality bonus payments, directly affecting its financial performance and market competitiveness.
- Industry Implications: Should the court side with Elevance, CMS may be compelled to revisit its ratings process, potentially impacting payments and competitive positioning across the industry, which could lead to similar adjustments for other insurers.
- Future Outlook: Elevance argues that all insurers should be treated under the same rules post-rating release rather than allowing company-specific adjustments, and the outcome of this lawsuit could significantly influence the future earnings growth of insurers heavily reliant on Medicare Advantage.
See More
Plus Therapeutics Signs Agreement with Elevance Health for CNSide Assay
- Agreement Signed: Plus Therapeutics' wholly owned subsidiary CNSide Diagnostics has signed a national agreement with Elevance Health, effective May 1, 2026, marking a strategic expansion in tumor cell enumeration testing.
- Testing Platform Benefits: The CNSide CSF assay platform determines leptomeningeal metastases in patients, utilizing quantitative analyses to detect malignant cell residues, and has proven effective in the FORESEE clinical trial with 92% sensitivity and 95% specificity.
- Market Coverage Expansion: The contract with Elevance is expected to add 45.5 million users, bringing total coverage to 126 million people across the U.S., significantly enhancing market penetration and brand influence.
- Positive Stock Reaction: PSTV closed at $4.26, up 7.58%, and is trading at $4.28 in pre-market, indicating strong market expectations regarding this partnership.
See More
Plus Therapeutics Partners with Elevance Health for Cancer Screening Test Coverage Expansion
- Agreement Reached: Plus Therapeutics' subsidiary CNSide Diagnostics has signed an agreement with Elevance Health to expand coverage for a cancer screening test, allowing Elevance members to get reimbursed for the CNSide test, benefiting approximately 45.4 million people in the U.S.
- Test Overview: The CNSide test is designed to help patients identify whether their tumor cells have spread to the central nervous system, currently available exclusively through CNSide Diagnostics to U.S. healthcare professionals, enhancing market recognition of the test.
- Expanded Coverage: The agreement takes effect on May 1, 2026, and is expected to widen the test's availability to 126 million people, significantly boosting Plus Therapeutics' competitiveness in the cancer screening market.
- Market Impact: This agreement not only enhances Plus Therapeutics' market position but may also drive its stock price up, reflecting investor confidence in the company's future growth potential.
See More
Elevance Health and IFF Transform School Fitness Space
- Fitness Space Renovation: Thomas Carr Howe Middle School celebrated the transformation of its fitness and strength training area through a partnership with Elevance Health and the Impact Fitness Foundation, enhancing health and athletic opportunities for students.
- Ongoing Community Investment: This marks the fifth consecutive year that Elevance Health and IFF have invested in community fitness initiatives in Indianapolis schools, demonstrating the company's long-term commitment to youth health.
- Volunteer Engagement: More than 40 Elevance Health volunteers participated in the renovation, installing new flooring, fitness equipment, and storage systems to create a modern training environment aimed at supporting student wellness.
- Support for Female Athletes: The renovated facility will provide expanded opportunities for female student-athletes, helping them build confidence and leadership skills, reflecting Elevance Health's commitment to empowering women in sports.
See More
2027 Health Insurance Premiums May Rise 14%
- Premium Increase Trend: KFF's analysis reveals that 77 insurers across 16 states and Washington, D.C. are proposing a median premium increase of 14% for 2027, following a 20% rise in 2026, marking two consecutive years of double-digit hikes that exacerbate affordability issues.
- Enrollment Decline: Approximately 19 million people are covered under the Affordable Care Act, but enrollment has dropped by about 4 million this year due to the expiration of enhanced COVID-era subsidies, indicating that high premiums are deterring potential enrollees.
- Loss of Healthy Consumers: KFF highlights that rising premiums and the loss of subsidies discourage healthier individuals from enrolling, leaving insurers with a sicker member pool and higher medical costs, with insurers attributing roughly 4 percentage points of their requested premium increases for 2027 to this trend.
- Rising Medical Costs: Insurers cite increasing medical expenses, inflation, higher labor costs, and growing expenditures on GLP-1 weight-loss and diabetes treatments as key factors driving their need to raise premiums, reflecting the multifaceted pressures facing the industry.
See More
Cash-Generating Stocks with Growth Potential
- RingCentral's Declining Performance: Despite a free cash flow margin of 21.2%, RingCentral's average billings growth of only 5.2% over the past year indicates waning customer confidence, with projected sales growth slowing to 4.5% over the next 12 months, potentially diminishing its competitive edge.
- Avery Dennison's Growth Struggles: With a free cash flow margin of 9.3%, Avery Dennison has fallen short of organic revenue growth benchmarks, and its projected sales growth of just 3.8% for the next year, coupled with a mere 4.3% annual EPS growth over five years, suggests a need for product and strategy improvements.
- Elevance Health's Strong Potential: Elevance Health, with a free cash flow margin of 3.3%, boasts a 9.9% annualized sales growth and a substantial revenue base of $198.3 billion, providing leverage in the health insurance market, indicating a promising investment opportunity.
- Market Outlook Analysis: While RingCentral and Avery Dennison face growth challenges, Elevance Health's robust performance and market position make it a stock to watch, prompting investors to carefully assess the future market performance of these companies.
See More
Elevance Health Sues CMS Over Medicare Advantage Ratings
- Lawsuit Background: Elevance Health has filed a lawsuit against the Centers for Medicare & Medicaid Services (CMS), alleging unfair adjustments to a competitor's Medicare Advantage Star Ratings after finalization, claiming this created an uneven competitive landscape.
- Financial Impact: Elevance estimates that the disputed CMS decision cost it approximately $115 million in Medicare Advantage quality bonus payments, directly affecting its financial performance and market competitiveness.
- Industry Implications: Should the court side with Elevance, CMS may be compelled to revisit its ratings process, potentially impacting payments and competitive positioning across the industry, which could lead to similar adjustments for other insurers.
- Future Outlook: Elevance argues that all insurers should be treated under the same rules post-rating release rather than allowing company-specific adjustments, and the outcome of this lawsuit could significantly influence the future earnings growth of insurers heavily reliant on Medicare Advantage.
See More
Plus Therapeutics Signs Agreement with Elevance Health for CNSide Assay
- Agreement Signed: Plus Therapeutics' wholly owned subsidiary CNSide Diagnostics has signed a national agreement with Elevance Health, effective May 1, 2026, marking a strategic expansion in tumor cell enumeration testing.
- Testing Platform Benefits: The CNSide CSF assay platform determines leptomeningeal metastases in patients, utilizing quantitative analyses to detect malignant cell residues, and has proven effective in the FORESEE clinical trial with 92% sensitivity and 95% specificity.
- Market Coverage Expansion: The contract with Elevance is expected to add 45.5 million users, bringing total coverage to 126 million people across the U.S., significantly enhancing market penetration and brand influence.
- Positive Stock Reaction: PSTV closed at $4.26, up 7.58%, and is trading at $4.28 in pre-market, indicating strong market expectations regarding this partnership.
See More
Plus Therapeutics Partners with Elevance Health for Cancer Screening Test Coverage Expansion
- Agreement Reached: Plus Therapeutics' subsidiary CNSide Diagnostics has signed an agreement with Elevance Health to expand coverage for a cancer screening test, allowing Elevance members to get reimbursed for the CNSide test, benefiting approximately 45.4 million people in the U.S.
- Test Overview: The CNSide test is designed to help patients identify whether their tumor cells have spread to the central nervous system, currently available exclusively through CNSide Diagnostics to U.S. healthcare professionals, enhancing market recognition of the test.
- Expanded Coverage: The agreement takes effect on May 1, 2026, and is expected to widen the test's availability to 126 million people, significantly boosting Plus Therapeutics' competitiveness in the cancer screening market.
- Market Impact: This agreement not only enhances Plus Therapeutics' market position but may also drive its stock price up, reflecting investor confidence in the company's future growth potential.
See More
Elevance Health and IFF Transform School Fitness Space
- Fitness Space Renovation: Thomas Carr Howe Middle School celebrated the transformation of its fitness and strength training area through a partnership with Elevance Health and the Impact Fitness Foundation, enhancing health and athletic opportunities for students.
- Ongoing Community Investment: This marks the fifth consecutive year that Elevance Health and IFF have invested in community fitness initiatives in Indianapolis schools, demonstrating the company's long-term commitment to youth health.
- Volunteer Engagement: More than 40 Elevance Health volunteers participated in the renovation, installing new flooring, fitness equipment, and storage systems to create a modern training environment aimed at supporting student wellness.
- Support for Female Athletes: The renovated facility will provide expanded opportunities for female student-athletes, helping them build confidence and leadership skills, reflecting Elevance Health's commitment to empowering women in sports.
See More
